KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Recursion Pharmaceuticals (RXRX) Cash & Equivalents (2020 - 2025)

Recursion Pharmaceuticals' Cash & Equivalents history spans 6 years, with the latest figure at $743.3 million for Q4 2025.

  • For Q4 2025, Cash & Equivalents rose 25.06% year-over-year to $743.3 million; the TTM value through Dec 2025 reached $743.3 million, up 25.06%, while the annual FY2025 figure was $743.3 million, 25.06% up from the prior year.
  • Cash & Equivalents reached $743.3 million in Q4 2025 per RXRX's latest filing, up from $659.8 million in the prior quarter.
  • In the past five years, Cash & Equivalents ranged from a high of $743.3 million in Q4 2025 to a low of $214.1 million in Q1 2021.
  • Average Cash & Equivalents over 5 years is $468.6 million, with a median of $463.9 million recorded in 2022.
  • Peak YoY movement for Cash & Equivalents: surged 137.23% in 2022, then tumbled 37.37% in 2024.
  • A 5-year view of Cash & Equivalents shows it stood at $285.1 million in 2021, then skyrocketed by 92.87% to $549.9 million in 2022, then fell by 28.79% to $391.6 million in 2023, then surged by 51.79% to $594.4 million in 2024, then increased by 25.06% to $743.3 million in 2025.
  • Per Business Quant, the three most recent readings for RXRX's Cash & Equivalents are $743.3 million (Q4 2025), $659.8 million (Q3 2025), and $525.1 million (Q2 2025).